Physician profile
Eman Talia
NPI 1285254912
$3,220.62
in general payments reported to CMS, 2019-2025
26 companies · $447 in 2025
The $447 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $145 · 2022: $304 · 2023: $1,405 · 2024: $919 · 2025: $447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,771.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,771.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $509.67 | 2023 | Farxiga, Breztri, Fasenra |
| Amgen INC. | $386.63 | 2022-2023 | Otezla, Repatha |
| Neurelis, INC. | $181.55 | 2023-2025 | Valtoco |
| Pfizer INC. | $169.73 | 2023-2025 | |
| Inari Medical, INC. | $167.50 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Novo Nordisk INC | $160.38 | 2023-2024 | Wegovy, Rybelsus, Ozempic |
| E.R. Squibb & Sons, L.L.C. | $157.13 | 2023-2025 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.00 | 2023-2025 | Jardiance |
| Teva Pharmaceuticals USA, INC. | $122.45 | 2023 | Austedo |
| Lilly USA, LLC | $121.35 | 2024 | Zepbound |
| Dexcom, INC. | $114.29 | 2023 | Dexcom G7 Gss (161) |
| Novartis Pharmaceuticals Corporation | $108.29 | 2024-2025 | |
| Csl Behring | $86.10 | 2023-2024 | Kcentra |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $78.44 | 2023-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $70.83 | 2024-2025 | Zerbaxa, Dificid |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $65.23 | 2023 | |
| Alexion Pharmaceuticals, INC. | $45.83 | 2024-2025 | Ultomiris |
| Abbvie INC. | $41.47 | 2023-2025 | Teflaro |
| Viatris Specialty LLC | $41.12 | 2025 | Yupelri |
| Janssen Pharmaceuticals, INC | $34.49 | 2023-2024 | Xarelto |
| Boston Scientific Corporation | $31.62 | 2025 | Watchman Flx |
| Gilead Sciences, INC. | $27.13 | 2023-2024 | Veklury |
| Madrigal Pharmaceuticals | $17.12 | 2024 | Resmetirom |
| Alnylam Pharmaceuticals INC. | $15.99 | 2024 | Givlaari |
| Ucb, INC. | $15.77 | 2022 | |
| Smith+Nephew, INC. | $15.49 | 2024 | Collagenase Santyl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eman Talia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.